1
|
Liquidano-Perez E, Scheffler-Mendoza S, Bustamante-Ogando JC, Lopez-Herrera G. Correction to: Clinical Characteristics of Pediatric Patients with LRBA Deficiency in Mexico. J Clin Immunol 2024; 44:83. [PMID: 38573497 DOI: 10.1007/s10875-024-01697-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2024]
Affiliation(s)
- Eduardo Liquidano-Perez
- Department of Pediatric Clinical Immunology, National Institute of Pediatrics, Mexico City, Mexico
- Immunodeficiency Laboratory, National Institute of Pediatrics, Mexico City, Mexico
| | - Selma Scheffler-Mendoza
- Department of Pediatric Clinical Immunology, National Institute of Pediatrics, Mexico City, Mexico
| | | | | |
Collapse
|
2
|
Liquidano-Perez E, Scheffler-Mendoza S, Bustamante-Ogando JC, Lopez-Herrera G. To the Editor: Clinical Characteristics of Pediatric Patients with LRBA Deficiency in Mexico. J Clin Immunol 2024; 44:75. [PMID: 38443565 DOI: 10.1007/s10875-024-01679-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Accepted: 02/23/2024] [Indexed: 03/07/2024]
Affiliation(s)
- Eduardo Liquidano-Perez
- Department of Pediatric Clinical Immunology, National Institute of Pediatrics, Mexico City, Mexico
- Immunodeficiency Laboratory, National Institute of Pediatrics, Mexico City, Mexico
| | - Selma Scheffler-Mendoza
- Department of Pediatric Clinical Immunology, National Institute of Pediatrics, Mexico City, Mexico
| | | | | |
Collapse
|
3
|
Carrillo-Tapia E, Espinosa-Padilla SE, Perez-Perez D, Gonzalez-Serrano ME, Berron-Ruiz L, Espinosa-Rosales FJ, Rodriguez-Alba JC, Mújica-Guzman F, Yokoyama-Rebollar E, García-Flores JR, Herrera-González NE, Scheffler-Mendoza S, Yamazaki-Nakashimada MA, Staines-Boone AT, Lopez-Herrera G. Improved HUMARA for the Detection of X-Linked Agammaglobulinemia Carriers. Genet Test Mol Biomarkers 2022; 26:220-227. [PMID: 35394812 DOI: 10.1089/gtmb.2021.0139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background: Fragment analysis of exon 1 of the human androgen receptor, known as HUMARA, is a polymerase chain reaction (PCR)-based method for detecting X-linked agammaglobulinemia (XLA) carriers. This method takes advantage of X-chromosome inactivation (XCI) in female cells. XLA is caused by mutations in the Bruton tyrosine kinase (BTK) gene, located in Xq22.1. In this study, XCI is nonrandom or skewed in B cells. B cells with an active X-chromosome carrying a BTK mutation do not mature. Peripheral B cells in XLA carriers inactivate the mutated X-chromosome. Methods: HUMARA was performed using DNA from purified B cells and total leukocytes. DNA was digested using methylation-sensitive HhaI. The PCR of the HUMARA polymorphic marker was performed with the HhaI digested samples. The lengths of the PCR product were determined. If a suspected carrier showed skewed XCI in B cells, the marker length that corresponded with the length determined in the index patient indicated their carrier status. Results: HUMARA was conducted on purified B cells; this allowed easier identification of the mutated or inactive allele, as the active allele was enzymatically digested. Analysis of 30 possible carriers using modified HUMARA corroborated that the carrier status in all samples that were heterozygous for the marker using XCI calculation for leukocytes showed a Gaussian distribution, while the carrier B cell DNA showed a skewed XCI. Conclusion: Carrier status was successfully determined for most of the analyzed samples. B cell enrichment resulted in precise carrier determination data, reduced the sample size, and facilitated inactive and active allele identification.
Collapse
Affiliation(s)
| | - Sara E Espinosa-Padilla
- Laboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Ciudad de México, México
| | - Daniela Perez-Perez
- Laboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Ciudad de México, México.,Posgrado en Ciencias Biológicas, Universidad Nacional Autónoma de México, Ciudad de México, México
| | | | - Laura Berron-Ruiz
- Laboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Ciudad de México, México
| | | | | | - Fabiola Mújica-Guzman
- Laboratorio de Hematología, Instituto Nacional de Pediatría, Ciudad de México, México
| | | | - Jose R García-Flores
- Posgrado en Ciencias de la Salud, Escuela Superior de Medicina, Ciudad de México, México
| | | | | | | | | | - Gabriela Lopez-Herrera
- Laboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Ciudad de México, México
| |
Collapse
|
4
|
Romo-Gonzalez C, Bustamante-Ogando JC, Yamazaki-Nakashimada MA, Aviles-Jimenez F, Otero-Mendoza F, Espinosa-Rosales FJ, Espinosa-Padilla SE, Scheffler Mendoza SC, Durán-McKinster C, García-Romero MT, Saez-de-Ocariz M, Lopez-Herrera G. Infections With Enterohepatic Non-H. pylori Helicobacter Species in X-Linked Agammaglobulinemia: Clinical Cases and Review of the Literature. Front Cell Infect Microbiol 2022; 11:807136. [PMID: 35186782 PMCID: PMC8855360 DOI: 10.3389/fcimb.2021.807136] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2021] [Accepted: 12/03/2021] [Indexed: 11/29/2022] Open
Abstract
The genus Helicobacter is classified into two main groups according to its habitat: gastric and enterohepatic. Patients with X-linked agammaglobulinemia (XLA) appear to be associated with invasive infection with enterohepatic non-Helicobacter pylori species (NHPH), mainly H. cinaedi and H. bilis. Such infections are difficult to control and have a high potential for recurrence. The spectrum of illnesses caused by these species includes recurrent fever, bacteremia, arthritis, osteomyelitis, cellulitis, abdominal abscesses, and pyoderma gangrenosum-like ulcer. The presence of these Helicobacters is particularly difficult to diagnose and eradicate, as they are very fastidious bacteria and present resistance to several types of antibiotics. We report two clinical cases of XLA patients infected with H. bilis. These infections were chronic in these patients and could not be eradicated in one of them. We also review the cases of enterohepatic non-Helicobacter pylori species (NHPH) in patients with this inborn error of immunity.
Collapse
Affiliation(s)
- Carolina Romo-Gonzalez
- Laboratory of Experimental Bacteriology, National Institute of Pediatrics, Mexico City, Mexico
| | | | | | - Francisco Aviles-Jimenez
- Medical Unit in Infectious and Parasitic Diseases, High Specialty Medical Unit (UMAE) Pediatrics, National Medical Center (CMN) XXI Century, Mexican Social Security Institute (IMSS), Mexico City, Mexico
| | | | | | | | | | | | | | | | - Gabriela Lopez-Herrera
- Immunodeficiency Research Unit, National Institute of Pediatrics, Mexico City, Mexico
- *Correspondence: Gabriela Lopez-Herrera,
| |
Collapse
|
5
|
Castano-Jaramillo LM, Yamazaki-Nakashimada MA, O'Farrill-Romanillos PM, Muzquiz Zermeño D, Scheffler Mendoza SC, Venegas Montoya E, García Campos JA, Sánchez-Sánchez LM, Gámez González LB, Ramírez López JM, Bustamante Ogando JC, Vásquez-Echeverri E, Medina Torres EA, Lopez-Herrera G, Blancas Galicia L, Berrón Ruiz L, Staines-Boone AT, Espinosa-Padilla SE, Segura Mendez NH, Lugo Reyes SO. COVID-19 in the Context of Inborn Errors of Immunity: a Case Series of 31 Patients from Mexico. J Clin Immunol 2021; 41:1463-1478. [PMID: 34114122 PMCID: PMC8191444 DOI: 10.1007/s10875-021-01077-5] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Accepted: 05/25/2021] [Indexed: 12/15/2022]
Abstract
INTRODUCTION Patients with inborn errors of immunity (IEI) have a compromised or inappropriate immune response. Although they might be considered a high-risk group for severe SARS-CoV-2 infection, the reported impact of COVID-19 in these patients has been reassuring, while the differential susceptibility of distinct types of IEI remains unclear. OBJECTIVE We aimed to describe the findings and outcomes of our known patients with IEI who were diagnosed with COVID-19. METHODS In a retrospective study from March 2020 to February 2021, four centers in Mexico collected clinical, laboratory, and genetic data from pediatric and adult patients with known diagnoses of IEI who presented with COVID-19, based on compatible symptoms and positive SARS-CoV-2 testing or known household exposure. RESULTS We report 31 patients with known IEI from Mexico who presented with SARS-CoV-2 infection. Seventy-four percent were male, 52% were pediatric, and 81% survived. Their ages ranged from 5 months to 56 years, with a median of 17 years. Sixty-five percent had predominant antibody deficiencies, 48% were hospitalized, and 26% required ICU. Pediatric patients had a higher hospital admission rate than adults. Inpatient mortality was 40%, and ICU mortality rate was 63%. Forty-eight percent developed pneumonia, while 36% had evidence of hyperinflammation (4 adults and 7 children). Predominant laboratory features were lymphopenia and thrombocytopenia, seen in 70 and 44% of patients, respectively. The serum D-dimer median value was 2.6 (0.5-20.6) μg/mL, and the median highest ferritin value was 1015 (32-10,303) ng/mL. Intravenous immunoglobulin was used in 80% of patients. Other treatments included macrolides (39%) and corticosteroids (29%). Six patients died from secondary infection or uncontrolled systemic inflammation. DISCUSSION Although impaired immunity due to IEI may be a predisposing factor for severe COVID-19, most of our patients with IEI who acquired the SARS-CoV-2 infection developed a well-tolerated infection and survived, as have more than 80% of worldwide reported patients to date. An impaired immune or inflammatory response may be a predisposing factor for some and a protective factor for others. A systematic review of the literature could help identify those patients at risk of severe disease and complications. Healthcare-associated infections should be aggressively prevented.
Collapse
Affiliation(s)
| | | | - Patricia M O'Farrill-Romanillos
- Allergy and Immunology Department, Hospital de Especialidades, National Medical Center, Siglo XXI" IMSS, Mexico City, Mexico
| | | | | | - Edna Venegas Montoya
- Immunology Service, Hospital de Especialidades UMAE 25 IMSS, Monterrey, NL, Mexico
| | | | | | - Luisa B Gámez González
- Clinical Immunology Service, Hospital Infantil Especialidades de Chihuahua, Chihuahua, Mexico
| | | | - Juan Carlos Bustamante Ogando
- Immune Deficiencies Lab., National Institute of Pediatrics, Av Iman 1, Torre de Investigacion Piso 9, Insurgentes Cuicuilco, Coyoacan, 04530, Mexico City, Mexico
| | - Estefanía Vásquez-Echeverri
- Immune Deficiencies Lab., National Institute of Pediatrics, Av Iman 1, Torre de Investigacion Piso 9, Insurgentes Cuicuilco, Coyoacan, 04530, Mexico City, Mexico
| | - Edgar Alejandro Medina Torres
- Immune Deficiencies Lab., National Institute of Pediatrics, Av Iman 1, Torre de Investigacion Piso 9, Insurgentes Cuicuilco, Coyoacan, 04530, Mexico City, Mexico
| | - Gabriela Lopez-Herrera
- Immune Deficiencies Lab., National Institute of Pediatrics, Av Iman 1, Torre de Investigacion Piso 9, Insurgentes Cuicuilco, Coyoacan, 04530, Mexico City, Mexico
| | - Lizbeth Blancas Galicia
- Immune Deficiencies Lab., National Institute of Pediatrics, Av Iman 1, Torre de Investigacion Piso 9, Insurgentes Cuicuilco, Coyoacan, 04530, Mexico City, Mexico
| | - Laura Berrón Ruiz
- Immune Deficiencies Lab., National Institute of Pediatrics, Av Iman 1, Torre de Investigacion Piso 9, Insurgentes Cuicuilco, Coyoacan, 04530, Mexico City, Mexico
| | | | - Sara Elva Espinosa-Padilla
- Immune Deficiencies Lab., National Institute of Pediatrics, Av Iman 1, Torre de Investigacion Piso 9, Insurgentes Cuicuilco, Coyoacan, 04530, Mexico City, Mexico
| | - Nora Hilda Segura Mendez
- Allergy and Immunology Department, Hospital de Especialidades, National Medical Center, Siglo XXI" IMSS, Mexico City, Mexico
| | - Saul O Lugo Reyes
- Immune Deficiencies Lab., National Institute of Pediatrics, Av Iman 1, Torre de Investigacion Piso 9, Insurgentes Cuicuilco, Coyoacan, 04530, Mexico City, Mexico.
| |
Collapse
|
6
|
Moreno-Corona NC, Lopez-Ortega O, Flores Hermenegildo JM, Berron-Ruiz L, Rodriguez-Alba JC, Santos-Argumedo L, Lopez-Herrera G. Lipopolysaccharide-responsive beige-like anchor acts as a cAMP-dependent protein kinase anchoring protein in B cells. Scand J Immunol 2020; 92:e12922. [PMID: 32592188 DOI: 10.1111/sji.12922] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2019] [Revised: 05/15/2020] [Accepted: 06/21/2020] [Indexed: 01/04/2023]
Abstract
Lipopolysaccharide (LPS)-responsive beige-like anchor (LRBA) protein was initially described as a monogenetic cause for common variable immune deficiency, a syndrome characterized by low levels of B cells, defects in memory B cell differentiation and hypogammaglobulinaemia. LRBA was identified as an LPS up-regulated gene in B cells, macrophages and T cells. LRBA weighs 320 kDa and has 2863 amino acids. Its sequence contains multiple domains, suggesting that LRBA can act as a scaffolding protein. It contains two putative binding sites for cAMP-dependent kinase (PKA) regulatory subunits, suggesting this protein can act as A-kinase anchor protein (AKAP); however, physical interactions involving LRBA and PKA have not been demonstrated to date, and functional roles for such interactions are unexplored. In this work, we investigated physical interactions involving LRBA with regulatory subunits of PKA in human B cell lines and primary human B cells. PKA is a holoenzyme composed of two regulatory subunits, which can be RIα, RIβ, RIIα or RIIβ, and two catalytic subunits, Cα or Cβ. We co-immunoprecipitated LRBA using Ramos B cell lymphoma cells and observed that LRBA interacts with RIIβ. Interestingly, St-Ht31, an inhibitory peptide that disrupts AKAP interactions with regulatory subunits, reduced the amount of interacting protein. Furthermore, in primary human B cells, LRBA was induced after CD40L and IL-4 stimulation, and under such activation, we found that LRBA interacts with RIIα and RIIβ, suggesting that LRBA acts as an AKAP and binds RII subunits. Interestingly, we also identified that LRBA interacts with activation-induced cytidine deaminase in primary B cells, suggesting that it is involved in B cell function.
Collapse
Affiliation(s)
- Nidia Carolina Moreno-Corona
- Biomedicina Molecular, Centro de Investigacion y de Estudios Avanzados, Mexico City, Mexico.,Unidad de Investigacion en Inmunodeficiencias, Instituto Nacional de Pediatria, Mexico City, Mexico
| | - Orestes Lopez-Ortega
- Biomedicina Molecular, Centro de Investigacion y de Estudios Avanzados, Mexico City, Mexico
| | - Jose Mizael Flores Hermenegildo
- Biomedicina Molecular, Centro de Investigacion y de Estudios Avanzados, Mexico City, Mexico.,Unidad de Investigacion en Inmunodeficiencias, Instituto Nacional de Pediatria, Mexico City, Mexico
| | - Laura Berron-Ruiz
- Unidad de Investigacion en Inmunodeficiencias, Instituto Nacional de Pediatria, Mexico City, Mexico
| | - Juan Carlos Rodriguez-Alba
- Unidad de Citometria de Flujo, Instituto de Ciencias de la Salud, Universidad Veracruzana, Xalapa, Veracruz, Mexico
| | | | - Gabriela Lopez-Herrera
- Unidad de Investigacion en Inmunodeficiencias, Instituto Nacional de Pediatria, Mexico City, Mexico
| |
Collapse
|
7
|
Lopez-Herrera G, Tampella G, Pan-Hammarström Q, Herholz P, Trujillo-Vargas C, Phadwal K, Simon A, Moutschen M, Etzioni A, Mory A, Srugo I, Melamed D, Hultenby K, Liu C, Baronio M, Vitali M, Philippet P, Dideberg V, Aghamohammadi A, Rezaei N, Enright V, Du L, Salzer U, Eibel H, Pfeifer D, Veelken H, Stauss H, Lougaris V, Plebani A, Gertz E, Schäffer A, Hammarström L, Grimbacher B. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet 2012; 90:986-1001. [PMID: 22608502 PMCID: PMC3370280 DOI: 10.1016/j.ajhg.2012.04.015] [Citation(s) in RCA: 341] [Impact Index Per Article: 28.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2012] [Revised: 03/07/2012] [Accepted: 04/11/2012] [Indexed: 12/14/2022] Open
Abstract
Most autosomal genetic causes of childhood-onset hypogammaglobulinemia are currently not well understood. Most affected individuals are simplex cases, but both autosomal-dominant and autosomal-recessive inheritance have been described. We performed genetic linkage analysis in consanguineous families affected by hypogammaglobulinemia. Four consanguineous families with childhood-onset humoral immune deficiency and features of autoimmunity shared genotype evidence for a linkage interval on chromosome 4q. Sequencing of positional candidate genes revealed that in each family, affected individuals had a distinct homozygous mutation in LRBA (lipopolysaccharide responsive beige-like anchor protein). All LRBA mutations segregated with the disease because homozygous individuals showed hypogammaglobulinemia and autoimmunity, whereas heterozygous individuals were healthy. These mutations were absent in healthy controls. Individuals with homozygous LRBA mutations had no LRBA, had disturbed B cell development, defective in vitro B cell activation, plasmablast formation, and immunoglobulin secretion, and had low proliferative responses. We conclude that mutations in LRBA cause an immune deficiency characterized by defects in B cell activation and autophagy and by susceptibility to apoptosis, all of which are associated with a clinical phenotype of hypogammaglobulinemia and autoimmunity.
Collapse
Affiliation(s)
- Gabriela Lopez-Herrera
- Department of Immunology, Division of Infection and Immunity, University College London, Royal Free Hospital, London NW3 2QG, UK
- Immunodeficiency Research Unit, National Institute of Pediatrics, Mexico City 04530, Mexico
| | - Giacomo Tampella
- Pediatrics Clinic and Institute of Molecular Medicine A. Novicelli, University of Brescia, Spedali Civili di Brescia, Brescia 25123, Italy
| | - Qiang Pan-Hammarström
- Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, SE-14186 Stockholm, Sweden
| | - Peer Herholz
- Centre of Chronic Immunodeficiency, University Medical Centre, 79108 Freiburg, Germany
| | - Claudia M. Trujillo-Vargas
- Department of Immunology, Division of Infection and Immunity, University College London, Royal Free Hospital, London NW3 2QG, UK
- Group of Primary Immunodeficiencies, University of Antioquia, Medellin 1226, Colombia
| | - Kanchan Phadwal
- Biomedical Research Centre Translational Immunology Lab, National Institute for Health Research, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
| | - Anna Katharina Simon
- Biomedical Research Centre Translational Immunology Lab, National Institute for Health Research, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
- Medcial Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
| | - Michel Moutschen
- University of Liège Center of Immunology, Laboratory of Immunoendocrinology, Institute of Pathology, Liège-Sart Tilman 4000, Belgium
| | - Amos Etzioni
- Division of Pediatrics and Immunology, Rappaport School of Medicine, Technion, Haifa 31096, Israel
| | - Adi Mory
- Division of Pediatrics and Immunology, Rappaport School of Medicine, Technion, Haifa 31096, Israel
| | - Izhak Srugo
- Division of Pediatrics and Immunology, Rappaport School of Medicine, Technion, Haifa 31096, Israel
| | - Doron Melamed
- Division of Pediatrics and Immunology, Rappaport School of Medicine, Technion, Haifa 31096, Israel
| | - Kjell Hultenby
- Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, SE-14186 Stockholm, Sweden
| | - Chonghai Liu
- Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, SE-14186 Stockholm, Sweden
- Department of Pediatrics, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, China
| | - Manuela Baronio
- Pediatrics Clinic and Institute of Molecular Medicine A. Novicelli, University of Brescia, Spedali Civili di Brescia, Brescia 25123, Italy
| | - Massimiliano Vitali
- Pediatrics Clinic and Institute of Molecular Medicine A. Novicelli, University of Brescia, Spedali Civili di Brescia, Brescia 25123, Italy
| | - Pierre Philippet
- Department of Pediatrics, Centre Hospitalier Chrétien-Esperance, Montegnée 4420, Belgium
| | - Vinciane Dideberg
- University of Liège, Center for Human Genetics, Liège-Sart Tilman B-4000, Belgium
| | - Asghar Aghamohammadi
- Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences. Tehran 14194, Iran
| | - Nima Rezaei
- Molecular Immunology Research Center and Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran 14194, Iran
| | - Victoria Enright
- Department of Immunology, Division of Infection and Immunity, University College London, Royal Free Hospital, London NW3 2QG, UK
| | - Likun Du
- Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, SE-14186 Stockholm, Sweden
| | - Ulrich Salzer
- Centre of Chronic Immunodeficiency, University Medical Centre, 79108 Freiburg, Germany
| | - Hermann Eibel
- Centre of Chronic Immunodeficiency, University Medical Centre, 79108 Freiburg, Germany
| | - Dietmar Pfeifer
- Department of Hematology and Oncology, Freiburg University Medical Center, Freiburg 79106, Germany
| | - Hendrik Veelken
- Department of Hematology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands
| | - Hans Stauss
- Department of Immunology, Division of Infection and Immunity, University College London, Royal Free Hospital, London NW3 2QG, UK
| | - Vassilios Lougaris
- Pediatrics Clinic and Institute of Molecular Medicine A. Novicelli, University of Brescia, Spedali Civili di Brescia, Brescia 25123, Italy
| | - Alessandro Plebani
- Pediatrics Clinic and Institute of Molecular Medicine A. Novicelli, University of Brescia, Spedali Civili di Brescia, Brescia 25123, Italy
| | - E. Michael Gertz
- National Center for Biotechnology Information, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20894, USA
| | - Alejandro A. Schäffer
- National Center for Biotechnology Information, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20894, USA
| | - Lennart Hammarström
- Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, SE-14186 Stockholm, Sweden
| | - Bodo Grimbacher
- Department of Immunology, Division of Infection and Immunity, University College London, Royal Free Hospital, London NW3 2QG, UK
- Centre of Chronic Immunodeficiency, University Medical Centre, 79108 Freiburg, Germany
| |
Collapse
|
8
|
McGhee S, Engelhardt K, Winkler S, Sassi A, Woellner C, Lopez-Herrera G, Chen A, Kim H, Lloret MG, Schulze I, Ehl S, Thiel J, Pfeifer D, Veelken H, Niehues T, Siepermann K, Weinspach S, Reisli I, Keles S, Genel F, Kütükçüler N, Camcioglu Y, Somer A, Karakoc-Aydiner E, Barlan I. DOCK8 Deletions and Mutations Are Associated With The Autosomal Recessive Hyper-IgE Phenotype. J Allergy Clin Immunol 2010. [DOI: 10.1016/j.jaci.2010.01.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
9
|
Engelhardt KR, McGhee S, Winkler S, Sassi A, Woellner C, Lopez-Herrera G, Chen A, Kim HS, Lloret MG, Schulze I, Ehl S, Thiel J, Pfeifer D, Veelken H, Niehues T, Siepermann K, Weinspach S, Reisli I, Keles S, Genel F, Kütükçüler N, Camcioğlu Y, Somer A, Aydiner EK, Barlan I, Gennery A, Metin A, Degerliyurt A, Pietrogrande MC, Yeganeh M, Baz Z, Al-Tamemi S, Klein C, Puck JM, Holland SM, McCabe ERB, Grimbacher B, Chatila T. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol 2009; 124:1289-302.e4. [PMID: 20004785 PMCID: PMC2818862 DOI: 10.1016/j.jaci.2009.10.038] [Citation(s) in RCA: 352] [Impact Index Per Article: 23.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2009] [Revised: 10/22/2009] [Accepted: 10/26/2009] [Indexed: 01/01/2023]
Abstract
BACKGROUND The genetic etiologies of the hyper-IgE syndromes are diverse. Approximately 60% to 70% of patients with hyper-IgE syndrome have dominant mutations in STAT3, and a single patient was reported to have a homozygous TYK2 mutation. In the remaining patients with hyper-IgE syndrome, the genetic etiology has not yet been identified. OBJECTIVES We aimed to identify a gene that is mutated or deleted in autosomal recessive hyper-IgE syndrome. METHODS We performed genome-wide single nucleotide polymorphism analysis for 9 patients with autosomal-recessive hyper-IgE syndrome to locate copy number variations and homozygous haplotypes. Homozygosity mapping was performed with 12 patients from 7 additional families. The candidate gene was analyzed by genomic and cDNA sequencing to identify causative alleles in a total of 27 patients with autosomal-recessive hyper-IgE syndrome. RESULTS Subtelomeric biallelic microdeletions were identified in 5 patients at the terminus of chromosome 9p. In all 5 patients, the deleted interval involved dedicator of cytokinesis 8 (DOCK8), encoding a protein implicated in the regulation of the actin cytoskeleton. Sequencing of patients without large deletions revealed 16 patients from 9 unrelated families with distinct homozygous mutations in DOCK8 causing premature termination, frameshift, splice site disruption, and single exon deletions and microdeletions. DOCK8 deficiency was associated with impaired activation of CD4+ and CD8+T cells. CONCLUSION Autosomal-recessive mutations in DOCK8 are responsible for many, although not all, cases of autosomal-recessive hyper-IgE syndrome. DOCK8 disruption is associated with a phenotype of severe cellular immunodeficiency characterized by susceptibility to viral infections, atopic eczema, defective T-cell activation and T(h)17 cell differentiation, and impaired eosinophil homeostasis and dysregulation of IgE.
Collapse
Affiliation(s)
- Karin R. Engelhardt
- Dept. of Immunology and Molecular Pathology, Royal Free Hospital and University College London, London, UK
| | - Sean McGhee
- Division of Immunology, Allergy and Rheumatology, Department of Pediatrics, The David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA 90095
| | - Sabine Winkler
- Dept. of Immunology and Molecular Pathology, Royal Free Hospital and University College London, London, UK
| | - Atfa Sassi
- Laboratoire d’immunologie, vaccinologie et génétique moléculaire, Institut Pasteur de Tunis, Tunisia
| | - Cristina Woellner
- Dept. of Immunology and Molecular Pathology, Royal Free Hospital and University College London, London, UK
| | - Gabriela Lopez-Herrera
- Dept. of Immunology and Molecular Pathology, Royal Free Hospital and University College London, London, UK
| | - Andrew Chen
- Division of Immunology, Allergy and Rheumatology, Department of Pediatrics, The David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA 90095
| | - Hong Sook Kim
- Division of Immunology, Allergy and Rheumatology, Department of Pediatrics, The David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA 90095
| | - Maria Garcia Lloret
- Division of Immunology, Allergy and Rheumatology, Department of Pediatrics, The David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA 90095
| | - Ilka Schulze
- Centre of Chronic Immunodeficiency, University Medical Center, Freiburg, Germany
| | - Stephan Ehl
- Centre of Chronic Immunodeficiency, University Medical Center, Freiburg, Germany
| | - Jens Thiel
- Centre of Chronic Immunodeficiency, University Medical Center, Freiburg, Germany
| | - Dietmar Pfeifer
- Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany
| | - Hendrik Veelken
- Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany
| | - Tim Niehues
- HELIOS Klinikum Krefeld, Zentrum für Kinder- und Jugendmedizin, Krefeld, Germany
| | - Kathrin Siepermann
- HELIOS Klinikum Krefeld, Zentrum für Kinder- und Jugendmedizin, Krefeld, Germany
| | - Sebastian Weinspach
- Department of Pediatric Oncology, Hematology and Clinical Immunology, Center of Child and Adolescent Medicine, Heinrich-Heine-University Duesseldorf, Germany
| | - Ismail Reisli
- Selcuk University, Division of Pediatric Allergy and Immunology, Konya, Turkey
| | - Sevgi Keles
- Selcuk University, Division of Pediatric Allergy and Immunology, Konya, Turkey
| | - Ferah Genel
- Behcet Uz State Hospital Division of Pediatric Immunology, Izmir, Turkey
| | - Necil Kütükçüler
- Ege University Faculty of Medicine, Department of Pediatrics, Izmir, Turkey
| | - Yildiz Camcioğlu
- Istanbul University, Cerrahpasa Medical Faculty, Division of Pediatric Allergy-Immunology and Infectious Diseases, Istanbul,Turkey
| | - Ayper Somer
- Istanbul University, Istanbul Medical Faculty, Division of Infectious Diseases and Immunology, Istanbul, Turkey
| | - Elif Karakoc Aydiner
- Marmara University, Division of Pediatric Allergy and Immunology, Istanbul, Turkey
| | - Isil Barlan
- Marmara University, Division of Pediatric Allergy and Immunology, Istanbul, Turkey
| | - Andrew Gennery
- Institute of Cellular Medicine, Child Health, University of Newcastle upon Tyne, UK
| | - Ayse Metin
- SB Ankara Diskapi Children’s Hospital, Pediatric Immunology Unit, Ankara, Turkey
| | - Aydan Degerliyurt
- SB Ankara Diskapi Children’s Hospital, Pediatric Immunology Unit, Ankara, Turkey
| | - Maria C. Pietrogrande
- Department of Maternal and Pediatric Sciences, University of Milan, Fondazione IRCCS Policlinico Milano, Italy
| | - Mehdi Yeganeh
- Immunology Asthma and Allergy Research Institute, Children’s Medical Center, Tehran University of Medical Sciences, Iran
| | - Zeina Baz
- Department of Pediatrics, St. George Hospital University Medical Center, Beirut, Lebanon
| | - Salem Al-Tamemi
- Department of Pediatrics, Sultan Qaboos University, Muscat, Oman
| | - Christoph Klein
- Department of Pediatric Hematology/Oncology; Hannover Biomedical Research School, Hannover, Germany
| | | | - Steven M. Holland
- Laboratory of Clinical Infectious Diseases, NIAID, NIH, Bethesda, USA
| | - Edward R. B. McCabe
- Departments of Pediatrics, Human Genetics, and Bioengineering, and the Center for Society and Genetics, UCLA, Los Angeles, CA, USA
| | - Bodo Grimbacher
- Dept. of Immunology and Molecular Pathology, Royal Free Hospital and University College London, London, UK
| | - Talal Chatila
- Division of Immunology, Allergy and Rheumatology, Department of Pediatrics, The David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA 90095
| |
Collapse
|
10
|
Lopez-Herrera G, Berron-Ruiz L, Mogica-Martinez D, Espinosa-Rosales F, Santos-Argumedo L. Characterization of Bruton's tyrosine kinase mutations in Mexican patients with X-linked agammaglobulinemia. Mol Immunol 2007; 45:1094-8. [PMID: 17765309 DOI: 10.1016/j.molimm.2007.07.022] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2007] [Revised: 07/19/2007] [Accepted: 07/20/2007] [Indexed: 11/23/2022]
Abstract
X-linked agammaglobulinemia (XLA) is a humoral primary immunodeficiency in which affected patients have very low levels of peripheral B cells and a profound deficiency of all immunoglobulin isotypes. Mutations in the gene encoding for Bruton's tyrosine kinase (Btk) are responsible for most of the agammaglobulinemia. In this work, 14 Btk mutations responsible of causing XLA are described; eight of which are novel and six are mutations previously reported. Seven of the mutations were due to deletions and insertions of exons and introns, respectively, which suggest splicing defects. The others were missense mutations, five of which affect arginine residues and have been described, and two new which affect leucine and glutamine residues (L111P and E605G). Most of these mutations were located at the kinase domain of Btk and, less frequently, they were found in PH and SH2 domains. Protein expression was also affected since most of the patients did not express or express very low Btk.
Collapse
Affiliation(s)
- G Lopez-Herrera
- Departamento de Biomedicina Molecular, Centro de Investigacion y de Estudios Avanzados-IPN, Av. Instituto Politécnico Nacional 2508, Colonia Zacatenco, 07360 Mexico, D.F., Mexico
| | | | | | | | | |
Collapse
|
11
|
Hasan M, Lopez-Herrera G, Blomberg KEM, Lindvall JM, Berglöf A, Smith CIE, Vargas L. Defective Toll-like receptor 9-mediated cytokine production in B cells from Bruton's tyrosine kinase-deficient mice. Immunology 2007; 123:239-49. [PMID: 17725607 PMCID: PMC2433303 DOI: 10.1111/j.1365-2567.2007.02693.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Bruton's tyrosine kinase (Btk), a member of the Tec family of tyrosine kinases, plays an important role in the differentiation and activation of B cells. Mutations affecting Btk cause immunodeficiency in both humans and mice. In this study we set out to investigate the potential role of Btk in Toll-like receptor 9 (TLR9) activation and the production of pro-inflammatory cytokines such as interleukin (IL)-6, tumour necrosis factor (TNF)-alpha and IL-12p40. Our data show that Btk-deficient B cells respond more efficiently to CpG-DNA stimulation, producing significantly higher levels of pro-inflammatory cytokines but lower levels of the inhibitory cytokine IL-10. The quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis presented in this work shows that mRNA production of one of the important new members of the IL-12 family, IL-27, was significantly increased in Btk-deficient B cells after CpG-DNA stimulation. In this study, we demonstrate significant differences in CpG responsiveness between transitional 1 (T1) and T2 B cells for survival and maturation. Furthermore, TLR9 expression, measured both as protein and as mRNA, was increased in Btk-defective cells, especially after TLR9 stimulation. Collectively, these data provide evidence in support of the theory that Btk regulates both TLR9 activation and expression in mouse splenic B cells.
Collapse
Affiliation(s)
- Maroof Hasan
- Clinical Research Center, Department of Laboratory Medicine, Karolinska Institute, Karolinska University HospitalStockholm, Sweden
| | - Gabriela Lopez-Herrera
- Clinical Research Center, Department of Laboratory Medicine, Karolinska Institute, Karolinska University HospitalStockholm, Sweden
- Molecular Biomedicine Department at Center for Research and Advanced Studies, National Institute of TechnologyMexico City, Mexico
| | - K Emelie M Blomberg
- Clinical Research Center, Department of Laboratory Medicine, Karolinska Institute, Karolinska University HospitalStockholm, Sweden
| | | | - Anna Berglöf
- Clinical Research Center, Department of Laboratory Medicine, Karolinska Institute, Karolinska University HospitalStockholm, Sweden
| | - C I Edvard Smith
- Clinical Research Center, Department of Laboratory Medicine, Karolinska Institute, Karolinska University HospitalStockholm, Sweden
| | - Leonardo Vargas
- Clinical Research Center, Department of Laboratory Medicine, Karolinska Institute, Karolinska University HospitalStockholm, Sweden
| |
Collapse
|
12
|
Hasan M, Lopez-Herrera G, Blomberg EM, Berglof A, Edvard Smith C, Vargas L. 50 Potential Role of Bruton’s Tyrosine Kinase in Toll-like Receptor 9 Mediated Cytokine Production from B Cells. Cytokine 2007. [DOI: 10.1016/j.cyto.2007.07.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
13
|
Lopez-Herrera G, Berron-Ruiz L, Mogica D, Espinosa-Rosales FJ, Santos-Argumedo L. Analysis of X-linked agammaglobulinemia patients in Mexico (B222). The Journal of Immunology 2007. [DOI: 10.4049/jimmunol.178.supp.b222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Humoral immunodeficiences are very common in the National Registry of Primary Immunodeficiences in Mexico. Among the humoral defects, X-linked agammaglobulinemia (XLA) is one of the most frequently found. In this work we report Btk mutations for 13 unrelated XLA patients some of wich has not been reported previously, most of the mutations affect Btk kinase domain, and PH and SH2 domain affecting mutations were also detected. Btk protein expression was found to be present in the majority of patients, in some cases we detect low expression levels and it was absent in other patients.
Collapse
Affiliation(s)
- Gabriela Lopez-Herrera
- 1Biomedicina Molecular, CINVESTAV, Av. IPN 2508 San Pedro Zacatenco, Mexico city, 07000, Mexico,
- 2Immunology, Instituto Nacional de Pediatria, Av Insurgentes Sur 3700 Coyoacan, Mexico City, 04530, Mexico,
| | - Laura Berron-Ruiz
- 3Immunology, Instituto Nacional de Pediatria, Insurgentes Sur 3700 Coyoacan, Mexico city, 04530, Mexico,
| | - Dolores Mogica
- 4Inmunologia y Alergia, Centro Medico Nacional La Raza, IMSS, Calzada Vallejo s/n esq Jacarandas, Mexico city, 02200, Mexico
| | | | - Leopoldo Santos-Argumedo
- 1Biomedicina Molecular, CINVESTAV, Av. IPN 2508 San Pedro Zacatenco, Mexico city, 07000, Mexico,
| |
Collapse
|